Bio Pharma Dive
JUNE 27, 2024
A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.
Pharmaceutical Technology
JUNE 27, 2024
Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 27, 2024
Novo will pay $38 million in cash under the deal, which will also see 2seventy employees working on the program transfer to the Danish drugmaker.
Pharmaceutical Technology
JUNE 27, 2024
NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.
Bio Pharma Dive
JUNE 27, 2024
The pharma’s acquisition of Celsius is the latest in a string of deals by major drugmakers hunting anti-inflammatory medicines.
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 27, 2024
Years of life spent sitting on an office chair or a couch can have deadly health effects in the long run – but curling up with a regular cup of coffee might be a way to offset that harmful lifestyle.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JUNE 27, 2024
US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 27, 2024
Exports of Ayush and herbal products have reported a growth of 20.33 per cent during the first month of the current fiscal year, at $51.44 million as compared to $42.75 million during the same month of previous fiscal year.
Pharmaceutical Technology
JUNE 27, 2024
The recent raise will bring the biotech accelerator Curie.Bio’s total funds raised to nearly $1bn since it launched back in February 2023.
Rethinking Clinical Trials
JUNE 27, 2024
This podcast continues the discussion with Dr. Michael Pencina and Dr. Brian Anderson as they discuss discuss Public-Private Partnerships in the Trustworthy Health AI Ecosystem. Click on the recording below to listen to the podcast. NIH Pragmatic Trials Collaboratory · Podcast 49: Public-Private Partnerships in the Trustworthy Health AI Ecosystem Want to hear more?
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JUNE 27, 2024
Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.
Drug Patent Watch
JUNE 27, 2024
Introduction Patent portfolios are critical assets for pharmaceutical companies, providing market exclusivity and protecting revenue streams for drug products. Effective management of drug patent portfolios requires strategic planning, ongoing evaluation, and adaptation to the evolving pharmaceutical landscape. This article explores key best practices for optimizing drug patent portfolios to maximize value and maintain competitive advantage.
Pharmaceutical Technology
JUNE 27, 2024
Formation Bio has secured $372m in Series D funding to bolster its drug pipeline and expand its AI-driven drug development platform.
Fierce Pharma
JUNE 27, 2024
Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court. | Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court.
Pharmaceutical Technology
JUNE 27, 2024
The CDC ACIP has recommended the routine use of respiratory syncytial virus (RSV) vaccines for all adults aged 75 years and above.
BioSpace
JUNE 27, 2024
Rocket Pharmaceuticals’ gene therapy Kresladi has been hit with an FDA Complete Response Letter requesting additional chemistry, manufacturing and controls information to complete its review.
Pharmaceutical Technology
JUNE 27, 2024
As the funding market evolves, there is greater emphasis on companies having commercial plans and using AI for drug discovery.
pharmaphorum
JUNE 27, 2024
Explore a methodological approach for discovering the emotional patient journey through patient insights. Understand the importance of emotional connections in healthcare.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
JUNE 27, 2024
AbbVie has announced the receipt of accelerated approval from the US FDA for EPKINLY to treat adults with follicular lymphoma.
BioSpace
JUNE 27, 2024
AbbVie on Thursday announced it has acquired Celsius Therapeutics to expand its immunology portfolio with a first-in-class TREM1 inhibitor CEL383, following other big players looking to cash in on the hot immuno market.
Pharmaceutical Technology
JUNE 27, 2024
The US FDA has provided a complete response letter for Daiichi Sankyo and MSD’s BLA for patritumab deruxtecan to treat NSCLC.
BioSpace
JUNE 27, 2024
AbbVie and Merck/Daiichi Sankyo were hit this week with Complete Response Letters from the FDA, which rejected their respective drugs due to manufacturing issues.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
JUNE 27, 2024
Biotechs with AI-led drug pipelines appear to be enjoying higher investment attraction.
BioSpace
JUNE 27, 2024
Following the recently completed spinoff of cancer detection company Grail, sequencing giant Illumina said Thursday it expects to absorb a $1.47 billion goodwill impairment charge.
Outsourcing Pharma
JUNE 27, 2024
Artificial intelligence is showing great promise in the quest to unearth new drug candidates and disease targets faster than ever before.
Fierce Pharma
JUNE 27, 2024
With Regeneron’s treatment delayed, AbbVie is expanding its T-cell engager competition against Roche in blood cancer with a new FDA approval. | With Regeneron's treatment delayed, AbbVie is expanding its T-cell engager competition against Roche in blood cancer with a new FDA approval.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Outsourcing Pharma
JUNE 27, 2024
Personalized medicine has evolved to the point where it is transforming areas of healthcare, bringing hope to patients across the world.
pharmaphorum
JUNE 27, 2024
Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years, according to Verona.
BioSpace
JUNE 27, 2024
Expansion across its network will mean hundreds of new employees in Cincinnati, increased ability to get complex medicines to patients and more.
Outsourcing Pharma
JUNE 27, 2024
The pharmaceutical industry is making significant strides toward sustainability, with companies across the sector implementing various Environmental, Social, and Governance (ESG) initiatives.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
341 
Let's personalize your content